The U.S. Senate is set to vote on a non-binding War Powers Resolution urging President Trump to end U.S. military involvement in Iran unless Congress approves the war. The measure is largely symbolic but reflects growing bipartisan concern as fuel prices soar, impacting American consumers and political dynamics ahead of midterm elections. Democrats argue the president is violating constitutional war powers, while some Republicans, especially from affected states, are increasingly critical of the conflict. The vote highlights mounting pressure on lawmakers to address economic and political fallout from the war.
The U.S. Senate vote on ending the Iran war provides context for market activity on Pluang. For readers following U.S. stock movements, here is Pluang's market snapshot as of Sep 24, 2026 23:51 WIB: out of 150 priced US stocks, 80 rose and 70 fell. Notable movers include FCEL at USD 16.44 with a 1-day change of -4.31% and a typical hold time of 47 days, Affirm Holdings Inc (AFRM) at USD 70.83 up 4.02%, and IQIYI Inc (IQ) at USD 1.05 up 3.96%, with strong buy order activity on all three.
Costco reported a strong Q4 earnings per share (EPS) of $6.75, surpassing analyst expectations of $6.54, helped by tariff refunds. Although quarterly revenue of $93.87 billion slightly missed the $94.97 billion forecast, net sales rose 11.2% year-ove...
Vistry Group reported a significant first-half pre-tax loss of £661.3 million, driven by a £475 million goodwill impairment and increased building safety costs. Revenue fell to £1.42 billion, and operational performance weakened with fewer home compl...
Vail Resorts is set to report its Q3 2026 earnings on September 28, with analysts forecasting a loss per share around -$5.30 and revenue near $271 million, indicating flat performance year-over-year. The company’s financial health shows a high Debt-t...
Western Union faces multiple analyst downgrades with price targets cut to as low as $6.00, reflecting concerns over its profitability and competitive pressures from fintech rivals. The stock has fallen over 15% in the past month, trading near $6.00, ...
Citigroup lowered ACADIA Pharmaceuticals' price target from $40 to $33 after its Alzheimer's drug remlifanserin missed the primary goal in a mid-stage trial, causing a 10.5% stock drop. Despite this, Citigroup kept a "Buy" rating, citing promising se...
